| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
- | - | - | - | - | -84,617 | |
Net Income (Loss) Attributable to Parent | ||||||
-62,762 | -192,152 | -175,211 | -184,102 | -72,011 | - | |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||
Gain on sale of businesses | ||||||
-582 | 0 | -9,648 | 0 | 0 | - | |
Inventory provision | ||||||
- | - | 692 | 499 | 7 | 38 | |
Depreciation and amortization | ||||||
22,362 | 22,355 | 28,055 | 30,933 | 15,788 | 16,178 | |
Amortization of debt discounts and deferred financing offering cost | ||||||
5,702 | 5,018 | 4,417 | 108 | 0 | 0 | |
Change in fair value of derivatives liability | ||||||
0 | 7 | 264 | 1,228 | 0 | 0 | |
Impairment of equity securities | ||||||
0 | 1,750 | 0 | - | - | - | |
Impairment of intangible asset | ||||||
- | - | - | - | - | 24,150 | |
Unrealized changes in fair value of marketable securities | ||||||
- | - | - | 49 | 3,624 | -3,677 | |
Realized changes in fair value of marketable securities | ||||||
- | - | - | -49 | -3,971 | -109 | |
Deferred income taxes, net | ||||||
-560 | -3,769 | 5,059 | -23,385 | 0 | - | |
Stock-based compensation | ||||||
2,786 | 5,657 | 4,511 | 53,952 | 1,429 | 340 | |
Deferred income taxes, net | ||||||
- | - | - | - | - | 0 | |
Provision for bad debt expense | ||||||
-67 | 7 | 220 | 549 | 207 | 204 | |
Impairment of intangible assets | ||||||
3,977 | 0 | - | - | - | - | |
Loss from related party equity method investment | ||||||
-8,317 | -108,409 | -50,334 | -40,994 | -2,584 | 1,525 | |
Other noncash expense | ||||||
0 | 219 | 0 | 144 | 0 | 333 | |
Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | ||||||
-3,316 | -406 | -4 | -8,111 | -3,580 | -468 | |
Inventories | ||||||
302 | -343 | -196 | 570 | -982 | 2,308 | |
Related party receivables, net | ||||||
-687 | 306 | -623 | 325 | -228 | -120 | |
Prepaid expenses and other current assets | ||||||
16,629 | -2,270 | 588 | -3,495 | 4,245 | 132 | |
Deferred implementation costs | ||||||
0 | -48 | 2,214 | 5,952 | 4,155 | 0 | |
Accounts payable | ||||||
1,363 | -1,667 | -1,852 | -5,644 | 1,731 | 1,634 | |
Accrued and other current liabilities | ||||||
17,425 | -4,822 | -6,321 | 3,787 | 5,450 | -4,606 | |
Deferred revenue | ||||||
5,036 | 16,947 | 0 | - | - | - | |
Deferred revenue | ||||||
-4,933 | 570 | -999 | 3,853 | -21,158 | -928 | |
Related party payables, net | ||||||
5,961 | 6,026 | 2,832 | 4,220 | -4,738 | 7,582 | |
Change in operating lease right-of-use assets and liabilities | ||||||
-418 | 0 | - | - | - | - | |
Other operating assets and liabilities | ||||||
608 | -3,066 | 290 | 73 | 26 | 2,852 | |
Net cash used in operating activities | ||||||
-8,765 | -29,632 | -81,148 | -70,634 | -74,000 | -42,135 | |
Cash flows from investing activities: | ||||||
Proceeds from Divestiture of Businesses, Net of Cash Divested | ||||||
300 | 0 | 1,721 | 0 | 0 | - | |
Assignment of NantHealth Labs, net of cash acquired (see Note 20) | ||||||
0 | 68 | 0 | - | - | - | |
Proceeds from sale of business and equity method investment, net of cash transferred | ||||||
- | - | - | - | - | 12,842 | |
Acquisitions of businesses, net of cash acquired | ||||||
- | - | - | 78,725 | 50,548 | 2,306 | |
Deferred consideration for acquisition | ||||||
- | - | - | 4,358 | 0 | 0 | |
Purchases of property and equipment, including internal-use software | ||||||
4,590 | 10,546 | 13,636 | 15,780 | 8,244 | 7,637 | |
Proceeds from sales of property and equipment | ||||||
- | - | - | 138 | 0 | 0 | |
Purchases of intangible assets | ||||||
- | - | - | 0 | 5,000 | 4,000 | |
Investments in unconsolidated related parties | ||||||
- | - | - | 0 | 150,816 | 3,319 | |
Purchase of cost method investment | ||||||
- | - | - | 0 | 1,750 | 0 | |
Purchases of marketable securities | ||||||
- | - | 360 | 31 | 15,219 | 251,729 | |
Proceeds from sales of marketable securities | ||||||
- | - | - | 1,275 | 136,315 | 26,072 | |
Net cash provided by (used in) investing activities | ||||||
-4,290 | -10,478 | -12,275 | -88,765 | -95,262 | -230,077 | |
Cash flows from financing activities: | ||||||
Proceeds from insurance promissory note | ||||||
1,647 | 0 | - | 92,797 | 0 | 0 | |
Repayments of insurance promissory note | ||||||
1,409 | 0 | - | - | - | - | |
Proceeds from issuance of convertible notes to related party, net of offering costs | ||||||
- | - | - | 9,917 | 0 | 0 | |
Payment of long-term notes payable | ||||||
- | - | - | - | - | 1,975 | |
Earnout to former non-controlling interests | ||||||
- | - | - | - | - | 5,608 | |
Proceeds from (payment of) related party promissory notes | ||||||
- | - | - | 152,666 | -34,502 | 5,903 | |
Proceeds from issuance of membership interests | ||||||
- | - | - | 0 | 200,000 | 260,525 | |
Proceeds from initial public offering, net of offering costs | ||||||
- | - | - | 83,566 | 0 | 0 | |
Deemed capital contribution from Chairman and CEO | ||||||
- | - | - | 3,810 | 6,190 | 0 | |
Tax payments related to stock issued, net of stock withheld, for vested equity awards | ||||||
270 | 2,066 | 5,335 | 5,838 | 0 | 0 | |
Capital lease obligation payments | ||||||
- | 93 | 0 | - | - | - | |
Capital lease obligation payments | ||||||
0 | - | - | - | - | - | |
Payment of short-term notes payable | ||||||
- | - | - | 23,324 | 0 | 0 | |
Net cash used in financing activities | ||||||
-32 | -2,159 | -5,335 | 313,594 | 171,688 | 258,845 | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | ||||||
- | - | 65 | 169 | -136 | 49 | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | ||||||
25 | -300 | - | - | - | - | |
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||
-13,062 | -42,569 | -98,693 | - | - | - | |
Net (decrease) increase in cash and cash equivalents | ||||||
- | - | - | 154,364 | 2,290 | -13,318 | |
Supplemental disclosure of cash flow information | ||||||
Income taxes paid | ||||||
318 | 15 | - | - | - | - | |
Interest paid | ||||||
5,909 | 5,885 | 5,778 | - | - | - | |
Interest paid | ||||||
- | - | - | 11 | 2,193 | 31 | |
Interest received | ||||||
0 | 13 | 63 | 119 | 599 | 0 | |
Noncash investing and financing activities | ||||||
Purchases of property and equipment including internal use software | ||||||
- | - | - | 2,962 | 0 | 0 | |
Noncash consideration (common stock) from sale of Business (Note 3) and subsequent retirement of stock | ||||||
- | - | 42,749 | 0 | 0 | - | |
Purchases of property and equipment (including internal use software) | ||||||
1,068 | 529 | -759 | - | - | - | |
Assignment of NantHealth Labs (see Note 20) | ||||||
0 | 8,956 | 0 | - | - | - | |
Transfer of marketable securities as investment in unconsolidated related party | ||||||
- | - | - | 0 | 99,184 | 0 | |
Equity component reclassification of the convertible notes issuance, net | ||||||
- | - | - | 14,318 | 0 | 0 | |
Conversion of related party promissory note and interest payable to common stock | ||||||
- | - | - | 40,590 | 0 | 0 | |
Reclassification of redeemable common stock to common stock (former Series F units) | ||||||
- | - | - | 171,000 | 0 | 0 | |
NaviNet escrow receivable | ||||||
- | - | - | - | - | 0 | |
Accretion to redemption value of Series F / redeemable common stock | ||||||
- | - | - | 4,958 | 16,042 | 0 | |